| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on May 14, 2002
From the Heart and Kidney Institute, College of Pharmacy,
University of Houston, Houston,
Tex. * To whom correspondence should be addressed. E-mail: MLokhandwala{at}uh.edu.
AbstractEarlier
we have reported a defective dopamine D1-like
receptor function, which was accompanied by a decrease in D1 receptor
numbers and the inability of dopamine to inhibit Na,K-ATPase and
Na,H-exchanger in proximal tubules of hyperinsulinemic
obese Zucker rats. The present study was designed to test the
hypothesis that the defect in dopamine receptor function is a result of
hyperinsulinemia in obese rats. We designed
experiments to study D1 receptor function in obese Zucker rats treated
with rosiglitazone, as it lowers plasma insulin by improving insulin
sensitivity. A group of untreated lean and obese rats served as
controls. Rosiglitazone treatment (10 mg/kg orally, 4 weeks) caused
significant decreases in plasma insulin, blood glucose, and blood
pressure while causing an increase in renal sodium excretion compared
with untreated obese rats. In the isolated proximal tubules obtained
from untreated lean rats, dopamine caused concentration-dependent
inhibition of the Na,K-ATPase activity, but this inhibitory
effect was absent in untreated obese rats. In rosiglitazone-treated
obese rats, the inhibitory effect of dopamine on
Na,K-ATPase was significantly restored. This was accompanied by a
complete restoration of D1 receptor numbers in proximal tubular
membranes of treated obese rats. In another set of experiments,
treatment of primary proximal tubule epithelial cells in culture medium
with insulin caused a significant decrease in the D1 receptor
abundance, suggesting a direct role of insulin on D1 receptor
regulation. We conclude that hyperinsulinemia
causes downregulation of D1 receptor function and lowering of plasma
insulin levels leads to restoration of renal D1 receptor
function.
Revised on June 6, 2002
Rosiglitazone Treatment Restores Renal Dopamine
Receptor Function in Obese Zucker Rats
Dhananjay N. Umrani;
This article has been cited by other articles:
![]() |
S. Tiwari, S. Riazi, and C. A. Ecelbarger Insulin's impact on renal sodium transport and blood pressure in health, obesity, and diabetes Am J Physiol Renal Physiol, October 1, 2007; 293(4): F974 - F984. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Banday, F. R. Fazili, and M. F. Lokhandwala Oxidative Stress Causes Renal Dopamine D1 Receptor Dysfunction and Hypertension via Mechanisms That Involve Nuclear Factor-{kappa}B and Protein Kinase C J. Am. Soc. Nephrol., May 1, 2007; 18(5): 1446 - 1457. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Zanchi, C. Perregaux, M. Maillard, D. Cefai, J. Nussberger, and M. Burnier The PPAR{gamma} agonist pioglitazone modifies the vascular sodium-angiotensin II relationship in insulin-resistant rats Am J Physiol Endocrinol Metab, December 1, 2006; 291(6): E1228 - E1234. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Trivedi and M. F. Lokhandwala Rosiglitazone restores renal D1A receptor-Gs protein coupling by reducing receptor hyperphosphorylation in obese rats Am J Physiol Renal Physiol, August 1, 2005; 289(2): F298 - F304. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Khan, S. Riazi, X. Hu, J. Song, J. B. Wade, and C. A. Ecelbarger Regulation of the renal thiazide-sensitive Na-Cl cotransporter, blood pressure, and natriuresis in obese Zucker rats treated with rosiglitazone Am J Physiol Renal Physiol, August 1, 2005; 289(2): F442 - F450. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Banday, T. Hussain, and M. F. Lokhandwala Renal dopamine D1 receptor dysfunction is acquired and not inherited in obese Zucker rats Am J Physiol Renal Physiol, July 1, 2004; 287(1): F109 - F116. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Marwaha, A. A. Banday, and M. F. Lokhandwala Reduced renal dopamine D1 receptor function in streptozotocin-induced diabetic rats Am J Physiol Renal Physiol, March 1, 2004; 286(3): F451 - F457. [Abstract] [Full Text] |
||||
![]() |
M. Trivedi, A. Marwaha, and M. Lokhandwala Rosiglitazone Restores G-Protein Coupling, Recruitment, and Function of Renal Dopamine D1A Receptor in Obese Zucker Rats Hypertension, February 1, 2004; 43(2): 376 - 382. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. V. Desouza, S. N. Murthy, J. Diez, B. Dunne, A. S. Matta, V. A. Fonseca, and D. B. McNamara Differential Effects of Peroxisome Proliferator Activator Receptor-{alpha} and {gamma} Ligands on Intimal Hyperplasia After Balloon Catheter-Induced Vascular Injury in Zucker Rats Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2003; 8(4): 297 - 305. [Abstract] [PDF] |
||||
![]() |
A. A. Banday, M. Asghar, T. Hussain, and M. F. Lokhandwala Dopamine-Mediated Inhibition of Renal Na,K-ATPase Is Reduced by Insulin Hypertension, June 1, 2003; 41(6): 1353 - 1358. [Abstract] [Full Text] [PDF] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2002 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |